drugset / Trial / NCT04969939

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

NCT04969939

Phase 2 Completed 120 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo). Which treatment participants get is decided by chance. Participants will get 2 injections per week, on the same day. Participants will have to take the study medicine by use of a pre-filled pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show participants how. The study will last for about 26 weeks. Participants will have 17 visits at the clinic with the study doctor. At 4 of the clinic visits participants cannot eat and drink (water is allowed until 2 hours prior to the visit) for 8 hours before the visit.Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period. Women who are able to become pregnant can participate if they agree to use contraception during the study.

Timeline

Start
2021-07-15
Primary completion
2022-12-06
Completion
2023-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0165-1875 Unknown 1 mg Subcutaneous
Subject NNC0165-1875 Unknown 2 mg Subcutaneous
Background Semaglutide Peptide 2.4 mg Subcutaneous

Indications